Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Exclusivity For Omeprazole 40 Mg Challenged By Apotex

This article was originally published in The Pink Sheet Daily

Executive Summary

A federal appeals court should rule on the validity of FDA’s patent-based approach to awarding exclusivity for Paxil generics because “it is an absolute certainty” that Apotex will litigate the same issue for Prilosec 40 mg, company attorney Rakoczy tells the appellate judges.
Advertisement

Related Content

FDA's Patent-Based ANDA Exclusivity Policy Challenged By Apotex
FDA's Patent-Based ANDA Exclusivity Policy Challenged By Apotex
Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court
Neurontin, Paxil Generic Exclusivity Disputes Dismissed By Appeals Court
Apotex Challenge On Neurontin Generic Exclusivity May Be Too Late – Judges
Apotex Challenge On Neurontin Generic Exclusivity May Be Too Late – Judges
Apotex Challenge On Neurontin Generic Exclusivity May Be Too Late – Judges
"Shared Exclusivity" Ruling Could Impact Eight First-Time Generics Over Two Years, FDA Says
"Shared Exclusivity" Ruling Could Impact Eight First-Time Generics Over Two Years, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS058516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel